{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T05:31:18Z","timestamp":1793338278741,"version":"4.5.0"},"reference-count":128,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1038\/s41401-026-01867-w","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T02:25:51Z","timestamp":1784255151000},"page":"3312-3328","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Recent advances in function-enhanced antibody-drug conjugates: Antibody optimization and payload combination"],"prefix":"10.1038","volume":"47","author":[{"given":"Xin-tong","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"key":"1867_CR1","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","volume":"22","author":"C Dumontet","year":"2023","unstructured":"Dumontet C, Reichert JM, Senter PD, Lambert JM, Beck A. Antibody-drug conjugates come of age in oncology. Nat Rev Drug Discov. 2023;22:641\u201361.","journal-title":"Nat Rev Drug Discov"},{"key":"1867_CR2","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13045-025-01704-3","volume":"18","author":"R Wang","year":"2025","unstructured":"Wang R, Hu B, Pan Z, Mo C, Zhao X, Liu G, et al. Antibody-Drug Conjugates (ADCs): current and future biopharmaceuticals. J Hematol Oncol. 2025;18:51.","journal-title":"J Hematol Oncol"},{"key":"1867_CR3","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.3390\/pharmaceutics17091164","volume":"17","author":"IA Alradwan","year":"2025","unstructured":"Alradwan IA, Alnefaie MK, Al Fayez N, Aodah AH, Majrashi MA, Alturki M, et al. Strategic and chemical advances in antibody-drug conjugates. Pharmaceutics. 2025;17:1164.","journal-title":"Pharmaceutics"},{"key":"1867_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.671","volume":"5","author":"J He","year":"2024","unstructured":"He J, Zeng X, Wang C, Wang E, Li Y. Antibody-drug conjugates in cancer therapy: mechanisms and clinical studies. MedComm (2020). 2024;5:e671.","journal-title":"MedComm (2020)"},{"key":"1867_CR5","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s12272-023-01433-6","volume":"46","author":"Y Hong","year":"2023","unstructured":"Hong Y, Nam SM, Moon A. Antibody-drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry. Arch Pharmacol Res. 2023;46:131\u201348.","journal-title":"Arch Pharmacol Res."},{"key":"1867_CR6","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1158\/2159-8290.CD-20-1557","volume":"11","author":"O Metzger","year":"2021","unstructured":"Metzger O, Viale G, Stein S, Trippa L, Yardley DA, Mayer IA, et al. Impact of HER2 heterogeneity on treatment response of early-stage HER2-positive breast cancer: Phase II neoadjuvant clinical trial of T-DM1 combined with pertuzumab. Cancer Discov. 2021;11:2474\u201387.","journal-title":"Cancer Discov"},{"key":"1867_CR7","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1158\/1535-7163.MCT-17-0403","volume":"17","author":"M Sung","year":"2018","unstructured":"Sung M, Tan XZ, Lu BW, Golas J, Hosselet C, Wang F, et al. Caveolae-mediated endocytosis as a novel mechanism of resistance to Trastuzumab emtansine (T-DM1). Mol Cancer Ther. 2018;17:243\u201353.","journal-title":"Mol Cancer Ther"},{"key":"1867_CR8","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.2174\/0929867311320120006","volume":"20","author":"GL Beretta","year":"2013","unstructured":"Beretta GL, Gatti L, Perego P, Zaffaroni N. Camptothecin resistance in cancer: Insights into the molecular mechanisms of a DNA-damaging drug. Curr Med Chem. 2013;20:1541\u201365.","journal-title":"Curr Med Chem"},{"key":"1867_CR9","doi-asserted-by":"publisher","first-page":"7296","DOI":"10.1038\/sj.onc.1206935","volume":"22","author":"ZA Rasheed","year":"2003","unstructured":"Rasheed ZA, Rubin EH. Mechanisms of resistance to topoisomerase I-targeting drugs. Oncogene. 2003;22:7296\u2013304.","journal-title":"Oncogene"},{"key":"1867_CR10","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/s41568-025-00869-w","volume":"25","author":"A Zippelius","year":"2025","unstructured":"Zippelius A, Tolaney SM, Tarantino P, Balthasar JP, Thurber GM. Unveiling the molecular and immunological drivers of antibody-drug conjugates in cancer treatment. Nat Rev Cancer. 2025;25:925\u201344.","journal-title":"Nat Rev Cancer"},{"key":"1867_CR11","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","volume":"21","author":"K Tsuchikama","year":"2024","unstructured":"Tsuchikama K, Anami Y, Ha SYY, Yamazaki CM. Exploring the next generation of antibody-drug conjugates. Nat Rev Clin Oncol. 2024;21:203\u201323.","journal-title":"Nat Rev Clin Oncol"},{"key":"1867_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12645-026-00373-2","volume":"17","author":"HH Wang","year":"2026","unstructured":"Wang HH, Liu XL. Advance of nanobody drug conjugates (NDCs) for cancer therapy. Cancer Nanotechnol. 2026;17:21.","journal-title":"Cancer Nanotechnol"},{"key":"1867_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s40820-021-00762-9","volume":"14","author":"XL Xia","year":"2022","unstructured":"Xia XL, Yang XY, Huang W, Xia XX, Yan DY. Self-assembled nanomicelles of affibody-drug conjugate with excellent therapeutic property to cure ovary and breast cancers. Nano-Micro Lett. 2022;14:33.","journal-title":"Nano-Micro Lett"},{"key":"1867_CR14","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1158\/1538-7445.AM2019-215","volume":"79","author":"LA Laviolette","year":"2019","unstructured":"Laviolette LA, Guidi CJ, Reichen C, Qiu QF, Harris L, Schildknecht P, et al. Generation of site-specific DARPin\u00ae drug conjugates using EGFR as a model system. Cancer Res. 2019;79:215.","journal-title":"Cancer Res"},{"key":"1867_CR15","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1016\/j.apsb.2023.01.017","volume":"13","author":"JX He","year":"2023","unstructured":"He JX, Duan Q, Ran CY, Fu T, Liu Y, Tan WH. Recent progress of aptamer-drug conjugates in cancer therapy. Acta Pharm Sin B. 2023;13:1358\u201370.","journal-title":"Acta Pharm Sin B"},{"key":"1867_CR16","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.apsb.2022.07.020","volume":"13","author":"C Fu","year":"2023","unstructured":"Fu C, Yu LF, Miao YX, Liu XL, Yu ZJ, Wei MJ. Peptide-drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope? Acta Pharm Sin B. 2023;13:498\u2013516.","journal-title":"Acta Pharm Sin B"},{"key":"1867_CR17","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1021\/acs.molpharmaceut.3c01049","volume":"21","author":"TS Wang","year":"2024","unstructured":"Wang TS, Li MC, Wei RT, Wang XY, Lin ZZ, Chen JM, et al. Small molecule-drug conjugates emerge as a new promising approach for cancer treatment. Mol Pharmacol. 2024;21:1038\u201355.","journal-title":"Mol Pharmacol"},{"key":"1867_CR18","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1021\/acs.bioconjchem.5c00037","volume":"36","author":"Y Zheng","year":"2025","unstructured":"Zheng Y, Cheng H, Jiang SB, Tai WY. Fc multisite conjugation and prolonged delivery of the folate-targeted drug conjugate EC140. Bioconjugate Chem. 2025;36:762\u20139.","journal-title":"Bioconjugate Chem"},{"key":"1867_CR19","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s12272-023-01447-0","volume":"46","author":"R Maiti","year":"2023","unstructured":"Maiti R, Patel B, Patel N, Patel M, Patel A, Dhanesha N. Antibody drug conjugates as targeted cancer therapy: past development, present challenges and future opportunities. Arch Pharmacol Res. 2023;46:361\u201388.","journal-title":"Arch Pharmacol Res."},{"key":"1867_CR20","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s43018-020-00152-x","volume":"2","author":"O Demaria","year":"2021","unstructured":"Demaria O, Vivier E. ISACs take a Toll on tumors. Nat Cancer. 2021;2:12\u20133.","journal-title":"Nat Cancer"},{"key":"1867_CR21","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/d41573-021-00213-5","volume":"21","author":"A Mullard","year":"2022","unstructured":"Mullard A. Antibody-oligonucleotide conjugates enter the clinic. Nat Rev Drug Discov. 2022;21:6\u20138.","journal-title":"Nat Rev Drug Discov"},{"key":"1867_CR22","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1021\/acs.jmedchem.2c01791","volume":"66","author":"KB Hong","year":"2023","unstructured":"Hong KB, An H. Degrader-antibody conjugates: Emerging new modality. J Med Chem. 2023;66:140\u20138.","journal-title":"J Med Chem"},{"key":"1867_CR23","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s11912-022-01266-4","volume":"24","author":"F Giugliano","year":"2022","unstructured":"Giugliano F, Corti C, Tarantino P, Michelini F, Curigliano G. Bystander effect of antibody-drug conjugates: fact or fiction? Curr Oncol Rep. 2022;24:809\u201317.","journal-title":"Curr Oncol Rep"},{"key":"1867_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1459368","volume":"14","author":"YY Gao","year":"2025","unstructured":"Gao YY, Xia YW, Chen YX, Zhou SQ, Fang YY, Yu JR, et al. Key considerations based on pharmacokinetic\/pharmacodynamic in the design of antibody-drug conjugates. Front Oncol. 2025;14:1459368.","journal-title":"Front Oncol"},{"key":"1867_CR25","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13045-025-01752-9","volume":"18","author":"KX Zhou","year":"2025","unstructured":"Zhou KX, Liu XR, Zhu H. Overcoming resistance to antibody-drug conjugates: from mechanistic insights to cutting-edge strategies. J Hematol Oncol. 2025;18:96.","journal-title":"J Hematol Oncol"},{"key":"1867_CR26","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.jconrel.2023.05.032","volume":"359","author":"A Beishenaliev","year":"2023","unstructured":"Beishenaliev A, Loke YL, Goh SJ, Geo HN, Mugila M, Misran M, et al. Bispecific antibodies for targeted delivery of anti-cancer therapeutic agents: A review. J Control Release. 2023;359:268\u201386.","journal-title":"J Control Release"},{"key":"1867_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02489-2","volume":"24","author":"BN Chen","year":"2025","unstructured":"Chen BN, Zheng XH, Wu JL, Chen GM, Yu J, Xu Y, et al. Antibody-drug conjugates in cancer therapy: current landscape, challenges, and future directions. Mol Cancer. 2025;24:279.","journal-title":"Mol Cancer"},{"key":"1867_CR28","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1016\/j.apsb.2024.01.009","volume":"14","author":"Y Gu","year":"2024","unstructured":"Gu Y, Wang Z, Wang Y. Bispecific antibody drug conjugates: Making 1+1>2. Acta Pharm Sin B. 2024;14:1965\u201386.","journal-title":"Acta Pharm Sin B"},{"key":"1867_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmr.2025.100076","volume":"77","author":"YF Du","year":"2025","unstructured":"Du YF, Karatekin F, Wang WK, Hong WJ, Boopathy GTK. Cracking the EGFR code: Cancer biology, resistance mechanisms, and future therapeutic frontiers. Pharmacol Rev. 2025;77:100076.","journal-title":"Pharmacol Rev."},{"key":"1867_CR30","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.critrevonc.2016.03.009","volume":"101","author":"S Temraz","year":"2016","unstructured":"Temraz S, Mukherji D, Shamseddine A. Dual targeting of HER3 and EGFR in colorectal tumors might overcome anti-EGFR resistance. Crit Rev Oncol Hemat. 2016;101:151\u20137.","journal-title":"Crit Rev Oncol Hemat"},{"key":"1867_CR31","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S1470-2045(24)00159-1","volume":"25","author":"YX Ma","year":"2024","unstructured":"Ma YX, Huang Y, Zhao YY, Zhao S, Xue JH, Yang YP, et al. BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody- drug conjugate, in patients with locally advanced or metastatic solid tumours: afirst-in-human, open-label, multicentre, phase 1 study. Lancet Oncol. 2024;25:901\u201311.","journal-title":"Lancet Oncol"},{"key":"1867_CR32","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.1158\/1538-7445.AM2023-2642","volume":"83","author":"WL Wan","year":"2023","unstructured":"Wan WL, Zhao SW, Zhuo S, Zhang Y, Chen L, Li GR, et al. BL-B01D1, a novel EGFR x HER3-targeting ADC, demonstrates robust anti-tumor efficacy in preclinical evaluation. Cancer Res. 2023;83:2642.","journal-title":"Cancer Res"},{"key":"1867_CR33","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1158\/2159-8290.CD-12-0558","volume":"3","author":"A Bardelli","year":"2013","unstructured":"Bardelli A, Corso S, Bertotti A, Hobor S, Valtorta E, Siravegna G, et al. Amplification of the receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov. 2013;3:658\u201373.","journal-title":"Cancer Discov"},{"key":"1867_CR34","unstructured":"Comer FI, Mazor Y, Kasturirangan S, Du Q, Yang C, Buchanan AG, et al. inventors. New antibody molecule comprising first antigen-binding domain that binds epidermal growth factor receptor and second antigen-binding domain that binds cyclic-mesenchymal epithelial transit used to treat cancer e.g. lung and breast cancers. 2023;US2023183358."},{"key":"1867_CR35","doi-asserted-by":"publisher","first-page":"5736","DOI":"10.1158\/1538-7445.AM2023-5736","volume":"83","author":"F Comer","year":"2023","unstructured":"Comer F, Mazor Y, Hurt E, Yang C, Fleming R, Shandilya H, et al. AZD9592: An EGFR-cMET bispecific antibody-drug conjugate (ADC) targeting key oncogenic drivers in non-small-cell lung cancer (NSCLC) and beyond. Cancer Res. 2023;83:5736.","journal-title":"Cancer Res"},{"key":"1867_CR36","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1158\/1538-7445.AM2025-2961","volume":"85","author":"Y Zheng","year":"2025","unstructured":"Zheng Y, Rosfjord E, Christ S, Zalesak-Kravec S, Grenga I, Arnaldez F, et al. AZD9592, an EGFR\/cMET bispecific antibody-drug conjugate (ADC), demonstrates target-dependent efficacy in colorectal cancer (CRC) patient-derived xenograft (PDX) models. Cancer Res. 2025;85:2961.","journal-title":"Cancer Res"},{"key":"1867_CR37","doi-asserted-by":"publisher","first-page":"LB043","DOI":"10.1158\/1538-7445.AM2024-LB043","volume":"84","author":"W Wang","year":"2024","unstructured":"Wang W, Li J, Ma L, Xu M, Yin Q. VBC101-F11: An innovative EGFR\/cMet bispecific antibody drug conjugate (ADC) targeting key oncogenic drivers in solid tumors. Cancer Res. 2024;84:LB043.","journal-title":"Cancer Res"},{"key":"1867_CR38","doi-asserted-by":"publisher","first-page":"6580","DOI":"10.1158\/1538-7445.AM2024-6580","volume":"84","author":"Y Xiao","year":"2024","unstructured":"Xiao Y, Huang HY, Yin JH, Qiu X, Wang L, Liu HD, et al. A Novel EGFR x cMET bispecific ADC PRO1286 demonstrated broad antitumor activity and promising tolerability in preclinical models. Cancer Res. 2024;84:6580.","journal-title":"Cancer Res"},{"key":"1867_CR39","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2024.2441411","volume":"17","author":"A Synan","year":"2025","unstructured":"Synan A, Wu NC, Velazquez R, Gesner T, Logel C, Mueller K, et al. A bispecific antibody-drug conjugate targeting pCAD and CDH17 has antitumor activity and improved tumor-specificity. Mabs-Austin. 2025;17:2441411.","journal-title":"Mabs-Austin"},{"key":"1867_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-015-0448-4","volume":"14","author":"AF Vieira","year":"2015","unstructured":"Vieira AF, Paredes J. P-cadherin and the journey to cancer metastasis. Mol Cancer. 2015;14:178.","journal-title":"Mol Cancer"},{"key":"1867_CR41","first-page":"138","volume":"1806","author":"NP Lee","year":"2010","unstructured":"Lee NP, Poon RTP, Shek FH, Ng IOL, Luk JM. Role of cadherin-17 in oncogenesis and potential therapeutic implications in hepatocellular carcinoma. Bba-Rev Cancer. 2010;1806:138\u201345.","journal-title":"Bba-Rev Cancer"},{"key":"1867_CR42","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/s41420-025-02652-0","volume":"11","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Du J, Cui XH, Ling YH, Tang CW. Development of a bispecific CDH17-GUCY2C ADC bearing the ferroptosis inducer RSL3 for the treatment of colorectal cancer. Cell Death Discov. 2025;11:347.","journal-title":"Cell Death Discov"},{"key":"1867_CR43","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1080\/14728222.2021.1937124","volume":"25","author":"AA Entezari","year":"2021","unstructured":"Entezari AA, Snook AE, Waldman SA. Guanylyl cyclase 2C (GUCY2C) in gastrointestinal cancers: recent innovations and therapeutic potential. Expert Opin Ther Tar. 2021;25:335\u201346.","journal-title":"Expert Opin Ther Tar"},{"key":"1867_CR44","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40164-025-00624-9","volume":"14","author":"MY Luo","year":"2025","unstructured":"Luo MY, Wang XH, Yu GJ, Ji J, Li L, Song F. Development of a bispecific antibody-drug conjugate targeting EpCAM and CLDN3 for the treatment of multiple solid tumors. Exp Hematol Oncol. 2025;14:33.","journal-title":"Exp Hematol Oncol"},{"key":"1867_CR45","doi-asserted-by":"publisher","first-page":"S1000","DOI":"10.1016\/j.annonc.2024.08.1741","volume":"35","author":"R Berger","year":"2024","unstructured":"Berger R, Tolcher AW, Dorff TB, Okubo S, Abraham LS, Reilly R, et al. First-in-human study of ABBV-969, a dual variable antibody-drug conjugate (ADC), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Ann Oncol. 2024;35:S1000\u2013S1.","journal-title":"Ann Oncol"},{"key":"1867_CR46","doi-asserted-by":"crossref","unstructured":"Reilly RM. ABBV-969: a first-in-class dual-targeting PSMA-STEAP1 drug conjugate for the treatment of metastatic castrate-resistant prostate cancer. Cancer Res. 2025;85:Nd3-Nd.","DOI":"10.1158\/1538-7445.AM2025-ND03"},{"key":"1867_CR47","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1038\/s41401-024-01458-7","volume":"46","author":"MH Wang","year":"2025","unstructured":"Wang MH, Ma Q, Suthe SR, Hudson RE, Pan JY, Mikelis C, et al. Humanized dual-targeting antibody-drug conjugates specific to MET and RON receptors as a pharmaceutical strategy for the treatment of cancers exhibiting phenotypic heterogeneity. Acta Pharmacol Sin. 2025;46:1375\u201389.","journal-title":"Acta Pharmacol Sin."},{"key":"1867_CR48","doi-asserted-by":"publisher","first-page":"8439","DOI":"10.1074\/jbc.M117.818013","volume":"293","author":"V Oganesyan","year":"2018","unstructured":"Oganesyan V, Peng L, Bee JS, Li J, Perry SR, Comer F, et al. Structural insights into the mechanism of action of a biparatopic anti-HER2 antibody. J Biol Chem. 2018;293:8439\u201348.","journal-title":"J Biol Chem"},{"key":"1867_CR49","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ccell.2015.12.008","volume":"29","author":"JY Li","year":"2016","unstructured":"Li JY, Perry SR, Muniz-Medina V, Wang XZ, Wetzel LK, Rebelatto MC, et al. A biparatopic HER2-targeting antibody-drug conjugate induces tumor regression in primary models refractory to or ineligible for HER2-targeted therapy. Cancer Cell. 2016;29:117\u201329.","journal-title":"Cancer Cell"},{"key":"1867_CR50","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1158\/1535-7163.MCT-20-0014","volume":"20","author":"MD Pegram","year":"2021","unstructured":"Pegram MD, Hamilton EP, Tan AR, Storniolo AM, Balic K, Rosenbaum A, et al. First-in-Human, Phase 1 dose-escalation study of biparatopic anti-HER2 antibody-drug conjugate MEDI4276 in patients with HER2-positive advanced breast or gastric cancer. Mol Cancer Ther. 2021;20:1442\u201353.","journal-title":"Mol Cancer Ther"},{"key":"1867_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37029-3","volume":"14","author":"NE Weisser","year":"2023","unstructured":"Weisser NE, Sanches M, Escobar-Cabrera E, O\u2019Toole J, Whalen E, Chan PWY, et al. An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity. Nat Commun. 2023;14:1394.","journal-title":"Nat Commun"},{"key":"1867_CR52","doi-asserted-by":"crossref","unstructured":"Hamblett KJ, Barnscher SD, Davies RH, Hammond PW, Hernandez A, Wickman GR, et al. ZW49, a HER2 targeted biparatopic antibody drug conjugate for the treatment of HER2 expressing cancers. Cancer Res. 2019;79:P6-17-3.","DOI":"10.1158\/1538-7445.SABCS18-P6-17-13"},{"key":"1867_CR53","doi-asserted-by":"publisher","first-page":"S749","DOI":"10.1016\/j.annonc.2022.07.589","volume":"33","author":"K Jhaveri","year":"2022","unstructured":"Jhaveri K, Han H, Dotan E, Oh DY, Ferrario C, Tolcher A, et al. Preliminary results from a phase I study using the bispecific, human epidermal growth factor 2 (HER2)-targeting antibody-drug conjugate (ADC) zanidatamab zovodotin (ZW49) in solid cancers. Ann Oncol. 2022;33:S749\u2013S50.","journal-title":"Ann Oncol"},{"key":"1867_CR54","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00280-025-04863-9","volume":"96","author":"X Ji","year":"2026","unstructured":"Ji X, Yang YL, Ma C, Huang WQ, Guo SY, Wang LZ, et al. Recent advances in bispecific antibody-drug conjugates for breast cancer therapy. Cancer Chemoth Pharmacol. 2026;96:15.","journal-title":"Cancer Chemoth Pharmacol"},{"key":"1867_CR55","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1158\/1538-7445.AM2025-2872","volume":"85","author":"HH Guo","year":"2025","unstructured":"Guo HH, Du Y, Huang YY, Wang J, Yang QL, Jia JX, et al. DXC018: A novel HER2 dual-payload bispecific ADC with promising potential for gastrointestinal cancers and other solid tumors. Cancer Res. 2025;85:2872.","journal-title":"Cancer Res"},{"key":"1867_CR56","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1039\/D5CB00096C","volume":"6","author":"Q Xue","year":"2025","unstructured":"Xue Q, Peng J, Dai W, Wu Q, Jiao J, Hu Y, et al. A biparatopic HER2-targeting ADC constructed via site-specific glycan conjugation exhibits superior stability, safety, and efficacy. RSC Chem Biol. 2025;6:1284\u201396.","journal-title":"RSC Chem Biol"},{"key":"1867_CR57","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1200\/JCO.2025.43.16_suppl.1028","volume":"43","author":"YQ Du","year":"2025","unstructured":"Du YQ, Zhang J, Liu JQ, Li WF, Zhang QY, Lo LIS, et al. JSKN003, a biparatopic HER2-targeting ADC, in heavily pretreated HER2-positive breast cancer: a pooled analysis of early-phase studies. J Clin Oncol. 2025;43:1028.","journal-title":"J Clin Oncol."},{"key":"1867_CR58","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1158\/1535-7163.MCT-21-0009","volume":"20","author":"JO DaSilva","year":"2021","unstructured":"DaSilva JO, Yang KT, Surriga O, Nittoli T, Kunz A, Franklin MC, et al. A biparatopic antibody-drug conjugate to treat MET-expressing cancers, including those that are unresponsive to MET pathway blockade. Mol Cancer Ther. 2021;20:1966\u201376.","journal-title":"Mol Cancer Ther"},{"key":"1867_CR59","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1158\/1535-7163.MCT-22-0414","volume":"22","author":"AEP Bay","year":"2023","unstructured":"Bay AEP, Faulkner D, DaSilva JO, Young TM, Yang KT, Giurleo JT, et al. A Bispecific METxMET antibody-drug conjugate with cleavable linker Is processed in recycling and late endosomes. Mol Cancer Ther. 2023;22:357\u201370.","journal-title":"Mol Cancer Ther"},{"key":"1867_CR60","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS8593","volume":"40","author":"AE Drilon","year":"2022","unstructured":"Drilon AE, Awad MM, Gadgeel SM, Villaruz LC, Sabari JK, Perez J, et al. A phase 1\/2 study of REGN5093-M114, a METxMET antibody-drug conjugate, in patients with mesenchymal epithelial transition factor (MET)-overexpressing NSCLC. J Clin Oncol. 2022;40:2082\u20136.","journal-title":"J Clin Oncol"},{"key":"1867_CR61","doi-asserted-by":"publisher","first-page":"CT008","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS5611","volume":"39","author":"RL Porter","year":"2021","unstructured":"Porter RL, Veneris JT, Tayob N, West G, Polak M, Gardner J, et al. A phase 2, two-stage study of mirvetuximab soravtansine (IMGN853) in combination with pembrolizumab in patients with microsatellite stable (MSS) endometrial cancer (EC). J Clin Oncol. 2021;39:CT008.","journal-title":"J Clin Oncol"},{"key":"1867_CR62","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1158\/1538-7445.AM2020-2890","volume":"80","author":"O Ab","year":"2020","unstructured":"Ab O, Bartle LM, Lanieri L, Ponte JF, Qiu QF, Sikka S, et al. IMGN151-A next generation folate receptor alpha targeting antibody drug conjugate active against tumors with low, medium and high receptor expression. Cancer Res. 2020;80:2890.","journal-title":"Cancer Res"},{"key":"1867_CR63","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1158\/1538-7445.AM2025-349","volume":"85","author":"MH Li","year":"2025","unstructured":"Li MH, Li F, Sun YY, Che QR, Dong N, Tong L, et al. GenSci140, a potential best-in-class FR\u03b1-directed biparatopic ADC, for the treatment of platinum-resistant ovarian cancer. Cancer Res. 2025;85:349.","journal-title":"Cancer Res"},{"key":"1867_CR64","doi-asserted-by":"publisher","first-page":"LB222","DOI":"10.1158\/1538-7445.AM2025-LB222","volume":"85","author":"B Wang","year":"2025","unstructured":"Wang B, Xing JK, Zhou SX, Wu WW, Wu M, Zuo RM, et al. Preclinical characterization of IBI3010, a FRa targeting biparatopic antibody-drug conjugate (ADC), for the treatment of FR\u03b1 expressing tumors Free. Cancer Res. 2025;85:LB222.","journal-title":"Cancer Res"},{"key":"1867_CR65","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1158\/1535-7163.MCT-14-0798","volume":"14","author":"BECG de Goeij","year":"2015","unstructured":"de Goeij BECG, Satijn D, Freitag CM, Wubbolts R, Bleeker WK, Khasanov A, et al. High turnover of tissue factor enables efficient intracellular delivery of antibody-drug conjugates. Mol Cancer Ther. 2015;14:1130\u201340.","journal-title":"Mol Cancer Ther"},{"key":"1867_CR66","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.jconrel.2025.01.060","volume":"380","author":"Y Sung","year":"2025","unstructured":"Sung Y, Choi Y, Kim ES, Ryu JH, Kwon IC. Receptor-ligand interactions for optimized endocytosis in targeted therapies. J Control Release. 2025;380:524\u201338.","journal-title":"J Control Release"},{"key":"1867_CR67","doi-asserted-by":"publisher","first-page":"392","DOI":"10.4161\/mabs.27705","volume":"6","author":"BECG de Goeij","year":"2014","unstructured":"de Goeij BECG, Peipp M, de Haij S, van den Brink EN, Kellner C, Riedl T, et al. HER2 monoclonal antibodies that do not interfere with receptor heterodimerization-mediated signaling induce effective internalization and represent valuable components for rational antibody-drug conjugate design. Mabs-Austin. 2014;6:392\u2013402.","journal-title":"Mabs-Austin"},{"key":"1867_CR68","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1158\/1535-7163.MCT-16-0658","volume":"16","author":"J Andreev","year":"2017","unstructured":"Andreev J, Thambi N, Bay AEP, Delfino F, Martin J, Kelly MP, et al. Bispecific antibodies and antibody-drug conjugates (ADCs) bridging HER2 and prolactin receptor improve efficacy of HER2 ADCs. Mol Cancer Ther. 2017;16:681\u201393.","journal-title":"Mol Cancer Ther"},{"key":"1867_CR69","doi-asserted-by":"publisher","first-page":"10805","DOI":"10.1074\/jbc.M113.453373","volume":"288","author":"RM DeVay","year":"2013","unstructured":"DeVay RM, Shelton DL, Liang H. Characterization of proprotein convertase Subtilisin\/Kexin type 9 (PCSK9) trafficking reveals a novel lysosomal targeting mechanism via Amyloid precursor-like protein 2 (APLP2). J Biol Chem. 2013;288:10805\u201318.","journal-title":"J Biol Chem"},{"key":"1867_CR70","doi-asserted-by":"publisher","first-page":"16056","DOI":"10.3390\/ijms242216056","volume":"24","author":"WL Zhuang","year":"2023","unstructured":"Zhuang WL, Zhang W, Wang L, Xie LP, Feng J, Zhang BH, et al. Generation of a novel SORT1xHER2 bispecific antibody-drug conjugate targeting HER2-low-expression tumor. Int J Mol Sci. 2023;24:16056.","journal-title":"Int J Mol Sci"},{"key":"1867_CR71","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1158\/1535-7163.MCT-24-0319","volume":"24","author":"Z Wang","year":"2025","unstructured":"Wang Z, Zheng MJ, Li MY, Lu HQ, Liu NX, Chen YD, et al. Development and characterization of a lysosome-targeting SLC3A2\/PD-L1 bispecific antibody-drug conjugate for enhanced antitumor efficacy in solid tumors. Mol Cancer Ther. 2025;24:261\u201374.","journal-title":"Mol Cancer Ther"},{"key":"1867_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2021.116013","volume":"32","author":"A Yamaguchi","year":"2021","unstructured":"Yamaguchi A, Anami Y, Ha SYY, Roeder TJ, Xiong W, Lee J, et al. Chemical generation of small molecule-based bispecific antibody-drug conjugates for broadening the target scope. Bioorgan Med Chem. 2021;32:116013.","journal-title":"Bioorgan Med Chem"},{"key":"1867_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100279","volume":"2","author":"KG Geles","year":"2021","unstructured":"Geles KG, Gao YJ, Giannakou A, Sridharan L, Yamin TT, Zhang J, et al. NOTCH3-targeted antibody drug conjugates regress tumors by inducing apoptosis in receptor cells and through transendocytosis into ligand cells. Cell Rep Med. 2021;2:100279.","journal-title":"Cell Rep Med"},{"key":"1867_CR74","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-15838-8","volume":"12","author":"J Takahashi","year":"2022","unstructured":"Takahashi J, Nakamura S, Onuma I, Zhou Y, Yokoyama S, Sakurai H. Synchronous intracellular delivery of EGFR-targeted antibody-drug conjugates by p38-mediated non-canonical endocytosis. Sci Rep-Uk. 2022;12:11561.","journal-title":"Sci Rep-Uk"},{"key":"1867_CR75","doi-asserted-by":"publisher","first-page":"39912","DOI":"10.1021\/jacs.5c15047","volume":"147","author":"FZ Zhao","year":"2025","unstructured":"Zhao FZ, Wu Y, Schaefer K, Zhang Y, Miao K, Yao Z, et al. Hijacking extracellular targeted protein degrader-drug conjugates for enhanced drug delivery. J Am Chem Soc. 2025;147:39912\u201325.","journal-title":"J Am Chem Soc"},{"key":"1867_CR76","doi-asserted-by":"publisher","first-page":"26218","DOI":"10.1021\/acs.jmedchem.5c02262","volume":"68","author":"B Chen","year":"2025","unstructured":"Chen B, Bai J, Shi H, Hao R, Liang J, Tian H, et al. Degrader-drug conjugate (DDC) mediated immunochemotherapy for tumor treatment. J Med Chem. 2025;68:26218\u201333.","journal-title":"J Med Chem"},{"key":"1867_CR77","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.tips.2017.01.003","volume":"38","author":"G Guidotti","year":"2017","unstructured":"Guidotti G, Brambilla L, Rossi D. Cell-penetrating Peptides: from basic research to clinics. Trends Pharmacol Sci. 2017;38:406\u201324.","journal-title":"Trends Pharmacol Sci."},{"key":"1867_CR78","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1021\/acs.accounts.7b00221","volume":"50","author":"S Futaki","year":"2017","unstructured":"Futaki S, Nakase I. Cell-surface interactions on arginine-rich cell-penetrating peptides allow for multiplex modes of internalization. Acc Chem Res. 2017;50:2449\u201356.","journal-title":"Acc Chem Res"},{"key":"1867_CR79","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1021\/acs.accounts.7b00455","volume":"50","author":"A Walrant","year":"2017","unstructured":"Walrant A, Cardon S, Burlina F, Sagan S. Membrane crossing and membranotropic activity of cell-penetrating peptides: Dangerous Liaisons? Acc Chem Res. 2017;50:2968\u201375.","journal-title":"Acc Chem Res."},{"key":"1867_CR80","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.jconrel.2020.03.005","volume":"322","author":"M Sauter","year":"2020","unstructured":"Sauter M, Strieker M, Kleist C, Wischnjow A, Daniel V, Altmann A, et al. Improving antibody-based therapies by chemical engineering of antibodies with multimeric cell-penetrating peptides for elevated intracellular delivery. J Control Release. 2020;322:200\u20138.","journal-title":"J Control Release"},{"key":"1867_CR81","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3390\/ijms18010047","volume":"18","author":"C Staudt","year":"2017","unstructured":"Staudt C, Puissant E, Boonen M. Subcellular trafficking of mammalian lysosomal proteins: An extended view. Int J Mol Sci. 2017;18:47.","journal-title":"Int J Mol Sci"},{"key":"1867_CR82","first-page":"605","volume":"1793","author":"T Braulke","year":"2009","unstructured":"Braulke T, Bonifacino JS. Sorting of lysosomal proteins. Bba-Mol Cell Res. 2009;1793:605\u201314.","journal-title":"Bba-Mol Cell Res"},{"key":"1867_CR83","doi-asserted-by":"publisher","first-page":"3229","DOI":"10.1039\/D0OB00265H","volume":"18","author":"Y Han","year":"2020","unstructured":"Han Y, Da YF, Yu MJ, Cheng YP, Wang X, Xiong JL, et al. Protein labeling approach to improve lysosomal targeting and efficacy of antibody-drug conjugates. Org Biomol Chem. 2020;18:3229\u201333.","journal-title":"Org Biomol Chem"},{"key":"1867_CR84","doi-asserted-by":"publisher","first-page":"32933","DOI":"10.1021\/jacs.4c06160","volume":"146","author":"HX Liu","year":"2024","unstructured":"Liu HX, Fu ZJ, Han Y, Fang YK, Shen WJ, Chen ZC, et al. Conditionally activatable chimeras for tumor-specific membrane protein degradation. J Am Chem Soc. 2024;146:32933\u201341.","journal-title":"J Am Chem Soc"},{"key":"1867_CR85","doi-asserted-by":"publisher","first-page":"16377","DOI":"10.1021\/jacs.1c08521","volume":"143","author":"H Zhang","year":"2021","unstructured":"Zhang H, Han Y, Yang YF, Lin F, Li KX, Kong LH, et al. Covalently engineered nanobody chimeras for targeted membrane protein degradation. J Am Chem Soc. 2021;143:16377\u201382.","journal-title":"J Am Chem Soc"},{"key":"1867_CR86","doi-asserted-by":"publisher","first-page":"19107","DOI":"10.1021\/jacs.3c07687","volume":"145","author":"JF Yu","year":"2023","unstructured":"Yu JF, Li HA, Fang T, Yun CY, Liu X, Xu JY, et al. Harnessing the lysosomal sorting signals of the cation-independent Mannose-6-phosphate receptor for targeted degradation of membrane proteins. J Am Chem Soc. 2023;145:19107\u201319.","journal-title":"J Am Chem Soc"},{"key":"1867_CR87","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/s41573-022-00542-z","volume":"21","author":"L Boike","year":"2022","unstructured":"Boike L, Henning NJ, Nomura DK. Advances in covalent drug discovery. Nat Rev Drug Discov. 2022;21:881\u201398.","journal-title":"Nat Rev Drug Discov"},{"key":"1867_CR88","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cell.2020.05.028","volume":"182","author":"QK Li","year":"2020","unstructured":"Li QK, Chen Q, Klauser PC, Li MY, Zheng F, Wang NX, et al. Developing covalent protein drugs via proximity-enabled reactive therapeutics. Cell. 2020;182:85\u201397.e16.","journal-title":"Cell"},{"key":"1867_CR89","doi-asserted-by":"publisher","first-page":"7913","DOI":"10.1039\/D3SC01921G","volume":"14","author":"BC Yu","year":"2023","unstructured":"Yu BC, Cao L, Li SS, Klauser PC, Wang L. The proximity-enabled sulfur fluoride exchange reaction in the protein context. Chem Sci. 2023;14:7913\u201321.","journal-title":"Chem Sci"},{"key":"1867_CR90","doi-asserted-by":"publisher","first-page":"9430","DOI":"10.1002\/anie.201309399","volume":"53","author":"JJ Dong","year":"2014","unstructured":"Dong JJ, Krasnova L, Finn MG, Sharpless KB. Sulfur(VI) fluoride exchange (SuFEx): Another good reaction for click chemistry. Angew Chem Int Ed. 2014;53:9430\u201348.","journal-title":"Angew Chem Int Ed"},{"key":"1867_CR91","doi-asserted-by":"publisher","first-page":"19687","DOI":"10.1021\/jacs.5c02212","volume":"147","author":"XL Xia","year":"2025","unstructured":"Xia XL, Gao WH, Yang XY, Huang W, Xia XX, Yan DY. Chemically engineered affinity protein drugs for covalent targeted cancer therapy. J Am Chem Soc. 2025;147:19687\u2013701.","journal-title":"J Am Chem Soc"},{"key":"1867_CR92","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202517155","volume":"65","author":"WH Gao","year":"2026","unstructured":"Gao WH, Zhang CC, Yang XY, Liu YC, Wang Y, Zhao MQ, et al. Synergistic SuFEx-driven covalent cancer therapy using a HER2\/EGFR bivalent affinity protein drug. Angew Chem Int Ed. 2026;65:e17155.","journal-title":"Angew Chem Int Ed"},{"key":"1867_CR93","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.apsb.2024.12.036","volume":"15","author":"SJ Li","year":"2025","unstructured":"Li SJ, Zhao XY, Fu K, Zhu SL, Pan C, Yang C, et al. Resistance to antibody-drug conjugates: A review. Acta Pharm Sin B. 2025;15:737\u201356.","journal-title":"Acta Pharm Sin B"},{"key":"1867_CR94","doi-asserted-by":"publisher","first-page":"2498162","DOI":"10.1016\/j.ejmech.2024.116995","volume":"281","author":"JJ Tao","year":"2025","unstructured":"Tao JJ, Gu YL, Zhou W, Wang YX. Dual-payload antibody-drug conjugates: taking a dual shot. Eur J Med Chem. 2025;281:2498162.","journal-title":"Eur J Med Chem."},{"key":"1867_CR95","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1158\/0008-5472.CAN-09-3546","volume":"70","author":"YV Kovtun","year":"2010","unstructured":"Kovtun YV, Audette CA, Mayo MF, Jones GE, Doherty H, Maloney EK, et al. Antibody-maytansinoid conjugates designed to bypass multidrug resistance. Cancer Res. 2010;70:2528\u201337.","journal-title":"Cancer Res"},{"key":"1867_CR96","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1182\/blood.V124.21.1376.1376","volume":"124","author":"R Chen","year":"2014","unstructured":"Chen R, Hou J, Newman E, Kim Y, Donohue C, Forman SJ, et al. Downregulation of CD30, resistance to MMAE, and upregulation of MDR1 are all associated with resistance to brentuximab vedotin. Blood. 2014;124:1376\u201384.","journal-title":"Blood"},{"key":"1867_CR97","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1021\/bc0502917","volume":"17","author":"SO Doronina","year":"2006","unstructured":"Doronina SO, Mendelsohn BA, Bovee TD, Cerveny CG, Alley SC, Meyer DL, et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjugate Chem. 2006;17:114\u201324.","journal-title":"Bioconjugate Chem."},{"key":"1867_CR98","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1002\/anie.201608292","volume":"56","author":"MR Levengood","year":"2017","unstructured":"Levengood MR, Zhang XQ, Hunter JH, Emmerton KK, Miyamoto JB, Lewis TS, et al. Orthogonal cysteine protection enables homogeneous multi-drug antibody-drug conjugates. Angew Chem Int Ed. 2017;56:733\u20137.","journal-title":"Angew Chem Int Ed"},{"key":"1867_CR99","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23793-7","volume":"12","author":"CM Yamazaki","year":"2021","unstructured":"Yamazaki CM, Yamaguchi A, Anami Y, Xiong W, Otani Y, Lee J, et al. Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance. Nat Commun. 2021;12:3528.","journal-title":"Nat Commun"},{"key":"1867_CR100","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.3390\/pharmaceutics15082020","volume":"15","author":"CM Mckertish","year":"2023","unstructured":"Mckertish CM, Kayser V. A novel dual-payload ADC for the treatment of HER2+ breast and colon cancer. Pharmaceutics. 2023;15:2020.","journal-title":"Pharmaceutics"},{"key":"1867_CR101","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1038\/nprot.2017.058","volume":"12","author":"F Tang","year":"2017","unstructured":"Tang F, Wang LX, Huang W. Chemoenzymatic synthesis of glycoengineered IgG antibodies and glycosite-specific antibody-drug conjugates. Nat Protoc. 2017;12:1702\u201321.","journal-title":"Nat Protoc"},{"key":"1867_CR102","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1016\/j.apsb.2021.12.013","volume":"12","author":"W Shi","year":"2022","unstructured":"Shi W, Li WZ, Zhang JX, Li TH, Song YK, Zeng Y, et al. One-step synthesis of site-specific antibody-drug conjugates by reprograming IgG glycoengineering with LacNAc-based substrates. Acta Pharm Sin B. 2022;12:2417\u201328.","journal-title":"Acta Pharm Sin B"},{"key":"1867_CR103","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202204132","volume":"61","author":"Y Zeng","year":"2022","unstructured":"Zeng Y, Shi W, Dong Q, Li WZ, Zhang JX, Ren XL, et al. A traceless site-specific conjugation on native antibodies enables efficient one-step payload assembly. Angew Chem Int Ed. 2022;61:e202204132.","journal-title":"Angew Chem Int Ed"},{"key":"1867_CR104","first-page":"748","volume":"34","author":"CH Tang","year":"2023","unstructured":"Tang CH, Zeng Y, Zhang JX, Zheng X, Tang F, Yao X, et al. One-Pot assembly of dual-site-specific antibody-drug conjugates via glycan remodeling and affinity-directed traceless conjugation. Bioconjugate Chem. 2023;34:748\u201355.","journal-title":"Bioconjugate Chem"},{"key":"1867_CR105","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.1158\/1538-7445.AM2024-2600","volume":"84","author":"P Spycher","year":"2024","unstructured":"Spycher P, Fay R, Bertrand R, Probst P, Stark R, Santimaria R, et al. Novel dual TOP1i ADC inducing superior tumour growth inhibition at low-drug load vs. trastuzumab deruxtecan. Cancer Res. 2024;84:2600.","journal-title":"Cancer Res"},{"key":"1867_CR106","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2025.2498162","volume":"17","author":"M Wen","year":"2025","unstructured":"Wen M, Yu A, Park Y, Calarese D, Gerber HP, Yin G. Homogeneous antibody-drug conjugates with dual payloads: potential, methods and considerations. Mabs-Austin. 2025;17:2498162.","journal-title":"Mabs-Austin"},{"key":"1867_CR107","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13045-022-01397-y","volume":"16","author":"L Conilh","year":"2023","unstructured":"Conilh L, Sadilkova L, Viricel W, Dumontet C. Payload diversification: a key step in the development of antibody-drug conjugates. J Hematol Oncol. 2023;16:3.","journal-title":"J Hematol Oncol"},{"key":"1867_CR108","doi-asserted-by":"publisher","first-page":"3617","DOI":"10.1016\/j.bmcl.2018.10.043","volume":"28","author":"A Kumar","year":"2018","unstructured":"Kumar A, Kinneer K, Masterson L, Ezeadi E, Howard P, Wu H, et al. Synthesis of a heterotrifunctional linker for the site-specific preparation of antibody-drug conjugates with two distinct warheads. Bioorg Med Chem Lett. 2018;28:3617\u201321.","journal-title":"Bioorg Med Chem Lett"},{"key":"1867_CR109","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/abt\/tbz009","volume":"2","author":"N Nilchan","year":"2019","unstructured":"Nilchan N, Li X, Pedzisa L, Nanna AR, Roush WR, Rader C. Dual-mechanistic antibody-drug conjugate via site-specific selenocysteine\/cysteine conjugation. Antib Therapeut. 2019;2:71\u20138.","journal-title":"Antib Therapeut"},{"key":"1867_CR110","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1021\/acsmedchemlett.5c00209","volume":"16","author":"T Watanabe","year":"2025","unstructured":"Watanabe T, Iwai Y, Stofleth JT, Fujii T, Seki T, Matsuda Y. Homogeneous dual-payload antibody-drug conjugates produced by combined distinct conjugation strategies. Acs Med Chem Lett. 2025;16:1334\u20139.","journal-title":"Acs Med Chem Lett"},{"key":"1867_CR111","doi-asserted-by":"publisher","first-page":"7334","DOI":"10.1158\/1538-7445.AM2025-7334","volume":"85","author":"I Attinger-Toller","year":"2025","unstructured":"Attinger-Toller I, Probst P, Bertrand R, Fay R, Kallenberger L, Maurhofer P, et al. Targeting Nectin-4 with a first-in-class triple MMAE\/dual TOP1i payload ADC showing synergistic and durable activity across all target expression levels and favorable tolerability. Cancer Res. 2025;85:7334.","journal-title":"Cancer Res"},{"key":"1867_CR112","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1158\/1535-7163.MCT-25-0271","volume":"25","author":"P Ren","year":"2026","unstructured":"Ren P, Guan M, Tang J, Yin S, Qi L, Yue J, et al. A novel dual-payload ADC platform integrating exatecan and triptolide to enhance antitumor efficacy and overcome resistance. Mol Cancer Ther. 2026;25:529\u201340.","journal-title":"Mol Cancer Ther"},{"key":"1867_CR113","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1158\/1538-7445.AM2025-1585","volume":"85","author":"YH Zhao","year":"2025","unstructured":"Zhao YH, Ren PF, Guan ML, Tang J, Qi L, Fan XZ, et al. KH815, a novel dual-payload TROP2-directed antibody-drug conjugate, shows potent antitumor efficacy in pre-clinical tumor model. Cancer Res. 2025;85:1585.","journal-title":"Cancer Res"},{"key":"1867_CR114","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1158\/1078-0432.CCR-22-3640","volume":"29","author":"Y Pommier","year":"2023","unstructured":"Pommier Y, Thomas A. New life of topoisomerase I inhibitors as antibody-drug conjugate warheads. Clin Cancer Res. 2023;29:991\u20133.","journal-title":"Clin Cancer Res"},{"key":"1867_CR115","doi-asserted-by":"publisher","first-page":"S66","DOI":"10.1016\/j.ejca.2024.114687","volume":"211","author":"D Thakkar","year":"2024","unstructured":"Thakkar D, Dharmadhikari B, Zharkova O, Paliwal S, Toy W, Khoo G, et al. A novel HER2 targeted dual-payload ADC, HMBD-802, overcomes resistance to topoisomerase 1 inhibitor ADCs. Eur J Cancer. 2024;211:S66\u2013S7.","journal-title":"Eur J Cancer"},{"key":"1867_CR116","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1021\/acs.bioconjchem.5c00239","volume":"36","author":"WL Sun","year":"2025","unstructured":"Sun WL, Weng WN, Shi J, Ma BY, DeMarco KD, Gui F, et al. SPARC: A multipayload ADC architecture for programmable drug combinations. Bioconjugate Chem. 2025;36:2158\u201371.","journal-title":"Bioconjugate Chem"},{"key":"1867_CR117","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/d41586-019-03702-1","volume":"576","author":"O Demaria","year":"2019","unstructured":"Demaria O, Cornen S, Da\u00ebron M, Morel Y, Medzhitov R, Vivier E. Harnessing innate immunity in cancer therapy. Nature. 2019;576:45\u201356.","journal-title":"Nature"},{"key":"1867_CR118","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107160","volume":"203","author":"C Fu","year":"2024","unstructured":"Fu C, Tong WW, Yu LF, Miao YX, Wei Q, Yu ZJ, et al. When will the immune-stimulating antibody conjugates (ISACs) be transferred from bench to bedside? Pharmacol Res. 2024;203:107160.","journal-title":"Pharmacol Res."},{"key":"1867_CR119","doi-asserted-by":"publisher","first-page":"24968","DOI":"10.1021\/acs.jmedchem.5c01908","volume":"68","author":"ST Fang","year":"2025","unstructured":"Fang ST, Benjamin SR, Wu LN, Rahman MA, Elder KK, Ojo VT, et al. Dissecting the efficacy and immunogenicity of TLR7 agonist-antibody conjugates through the lens of Fc effector function, conjugation strategies, and linker cleavability. J Med Chem. 2025;68:24968\u201385.","journal-title":"J Med Chem"},{"key":"1867_CR120","doi-asserted-by":"publisher","first-page":"3848","DOI":"10.1158\/0008-5472.CAN-23-4099","volume":"84","author":"ZX Zhou","year":"2024","unstructured":"Zhou ZX, Si YN, Zhang JS, Chen K, George A, Kim S, et al. A dual-payload antibody-drug conjugate targeting CD276\/B7-H3 elicits cytotoxicity and immune activation in triple-negative breast cancer. Cancer Res. 2024;84:3848\u201363.","journal-title":"Cancer Res"},{"key":"1867_CR121","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1158\/1538-7445.AM2025-1805","volume":"85","author":"C Liu","year":"2025","unstructured":"Liu C, Liu Y, Zhang R. Dual-payload TME-activated ADC platform. Cancer Res. 2025;85:1805.","journal-title":"Cancer Res"},{"key":"1867_CR122","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1158\/1538-7445.AM2023-2640","volume":"83","author":"MJ Xiong","year":"2023","unstructured":"Xiong MJ, Fan BB, Gao XJ, Sun YJ, Lv C, Si Y, et al. An innovative site-specific dual-payload antibody drug conjugate (dpADC) combining a novel Topo1 inhibitor and an immune agonist delivers a strong immunogenic cell death (ICD) and antitumor response in vitro and in vivo. Cancer Res. 2023;83:2640.","journal-title":"Cancer Res"},{"key":"1867_CR123","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/s43018-025-00919-0","volume":"6","author":"BR Schrank","year":"2025","unstructured":"Schrank BR, Wang YF, Wu A, Tran N, Lee DY, Edwards J, et al. An antibody-toxin conjugate targeting CD47 linked to the bacterial toxin listeriolysin O for cancer immunotherapy. Nat Cancer. 2025;6:511\u201327.","journal-title":"Nat Cancer"},{"key":"1867_CR124","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41587-025-02987-0","volume":"44","author":"C Sheridan","year":"2026","unstructured":"Sheridan C. Now with oligos: antibody-oligonucleotide conjugates are the new drug modality to watch. Nat Biotechnol. 2026;44:3\u20135.","journal-title":"Nat Biotechnol"},{"key":"1867_CR125","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1310130","volume":"14","author":"XX Ma","year":"2023","unstructured":"Ma XX, Jiang J, An XY, Zu WT, Ma C, Zhang Z, et al. Advances in research based on antibody-cell conjugation. Front Immunol. 2023;14:1310130.","journal-title":"Front Immunol"},{"key":"1867_CR126","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2025.115648","volume":"224","author":"GB Armstrong","year":"2025","unstructured":"Armstrong GB, Graham H, Cheung A, Montaseri H, Burley GA, Karagiannis SN, et al. Antibody-drug conjugates as multimodal therapies against hard-to-treat cancers. Adv Drug Deliv Rev. 2025;224:115648.","journal-title":"Adv Drug Deliv Rev"},{"key":"1867_CR127","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/s00280-025-04848-8","volume":"95","author":"L Eltaib","year":"2025","unstructured":"Eltaib L, Afzal M, Maji C, Malathi H, Goyal K, Ali H, et al. Mechanisms of resistance to antibody-drug conjugates in cancer: molecular barriers and pharmacological solutions. Cancer Chemoth Pharmacol. 2025;95:118.","journal-title":"Cancer Chemoth Pharmacol."},{"key":"1867_CR128","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1158\/1538-7445.AM2026-1675","volume":"86","author":"JM Fang","year":"2026","unstructured":"Fang JM, Li D, Jiang J, Li YH, Zhang W, Min XS, et al. Payload-recycling ADCs (PR-ADCs): A novel ADC platform for reducing free-payload toxicity and enhancing therapeutic index. Cancer Res. 2026;86:1675.","journal-title":"Cancer Res"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01867-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01867-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01867-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T04:47:39Z","timestamp":1793335659000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01867-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":128,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1867"],"URL":"https:\/\/doi.org\/10.1038\/s41401-026-01867-w","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"assertion":[{"value":"1 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author declares no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}